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BCL-2 positivity, low TOPOIIα expression and high MVD 
survived 80 months without any evidence of cancer dis-
ease, whereas DFS for all other patients was significantly 
(P = 0.022) lower (76.5 %).
Conclusion Combination of three parameters: BCL-2 
positivity, low topoisomerase IIα expression and high 
MVD, allows to identify subgroup of BC patients with 
very good prognosis after adjuvant anthracycline-based 
chemotherapy.
Keywords Early breast cancer patients · Anthracyclines · 
Potential prognostic factors
Introduction
Adjuvant systemic therapy of patients with early advanced 
breast cancer (BC) significantly reduces recurrence risk 
and overall mortality. Anthracyclines (ATC) are the most 
commonly used drugs in the adjuvant chemotherapy (CT) 
of breast cancer. The last meta-analysis of Early Breast 
Cancer Trialists’ Collaborative Group demonstrated that 
regimens based on higher dosages of ATC are associated 
with around 4 % reduction of recurrence rate and overall 
mortality as compared with cyclophosphamide, methotrex-
ate and fluorouracil scheme (CMF) (EBCTCG et al. 2012). 
There is a possibility to improve treatment outcome by 
more differentiated therapy, tailored to the biological char-
acteristics of the tumour cells. For this purpose, it is neces-
sary to undertake translational researches, consisting in the 
development of biological prognostic and predictive factors 
for adjuvant chemotherapy based on ATC. Today, there is 
no reliable prognostic factor which allows discrimination 
between patients who will benefit from adjuvant ATC treat-
ment and those who will not. In our previous papers, in the 
Abstract 
Purpose The aim of this retrospective study was to inves-
tigate the effect of B cell lymphoma 2 (BCL-2) expression 
on disease-free survival (DFS) in 172 early breast cancer 
(BC) patients treated with anthracycline-based adjuvant 
chemotherapy. We have reanalysed follow-up data in these 
patient groups, and therefore, the relation between DFS 
and other tumour biological features [expression of oes-
trogen (ER) and progesterone (PgR) receptors, cytokera-
tin 5/6 (CK5/6), HER2, topoisomerase IIα (TOPOIIα), 
Ki-67, P53 and microvessel density (MVD)] studied pre-
viously (Biesaga et al. in Breast 20(4):338–350, 2011, 
doi:10.1016/j.breast.2011.03.002, Pathol Oncol Res 18(4): 
949–960, 2012, doi:10.1007/s12253-012-9525-9) was also 
investigated.
Method Tumour biological features were assessed immu-
nohistochemically on paraffin-embedded sections obtained 
before treatment from 172 women with BC in stage T1–T2, 
N1–N2, M0.
Results In univariate analysis, longer DFS was found 
for patients having tumours with BCL-2 positivity 
(P = 0.005), low grade (P = 0.001), ER (P = 0.017) and 
PgR (P = 0.045) positivity, CK5/6 negativity (P = 0.021), 
low TOPOIIα expression (P = 0.003) and high MVD 
(P = 0.000). In multivariate analysis, BCL-2, TOPOIIα 
and MVD were independent parameters indicating patient 
prognosis. All patients (n = 18) characterized by tumour 
B. Biesaga (*) · J. Niemiec 
Department of Applied Radiobiology, Centre of Oncology,  
ul. Garncarska 11, 31-115 Kraków, Poland
e-mail: z5biesag@cyfronet.pl
M. Ziobro 
Department of Medical Oncology, Centre of Oncology,  
ul. Garncarska 11, 31-115 Kraków, Poland
2010 J Cancer Res Clin Oncol (2014) 140:2009–2019
1 3
group of 167 patients with breast cancers in clinical stage 
T1–T2, N1–N2, M0, treated with ATC in adjuvant setting, 
we have shown prognostic potential of topoisomerase IIα 
(TOPOIIα) expression (Biesaga et al. 2011) and tumour 
microvessel density (MVD) (Biesaga et al. 2012). How-
ever, chemotherapeutic agents such as ATC, irrespective of 
their intracellular target, act through induction of apopto-
sis in cancer cells. Therefore, alterations in the regulatory 
mechanism of apoptosis are responsible not only for cancer 
progression, but also for different response to treatment.
Antiapoptotic protein B cell lymphoma 2 (BCL-2) is 
one of the most extensively studied apoptosis regulators in 
translational studies, but its role in ATC resistance/sensi-
tivity is unclear. There are a few reports (see Table 1), in 
which prognostic potential of BCL-2 expression was inves-
tigated in the breast cancer patient groups consisting of 
subgroups of women treated with ATC in adjuvant setting, 
although in all these studies, expect one (Abdel-Fatah et al. 
2010) not analysed separately. In these studies, contradic-
tory results were obtained. Moreover, in two meta-analyses, 
performed to investigate BCL-2 prognostic potential, oppo-
site results were reported. Callagy et al. (2006) have shown 
positive prognostic significance of BCL-2 overexpression, 
whereas Yang et al. (2013) have found significant rela-
tion between BCL-2 negativity and good prognosis. These 
contradictions may be the effect of at least four causes: (1) 
other than antiapoptotic function of BCL-2 [the influence 
on cell cycle progression (Zinkel et al. 2006; Pietenpol 
et al. 1994)], (2) regulation of BCL-2 expression through 
oestrogen pathway (Perillo et al. 2000), (3) lack of homo-
geneity in patient group studied (according to clinical stage 
and adjuvant treatment type) and (4) differences in IHC 
Table 1  Studies on BCL-2 prognostic potential for adjuvant anthracycline-based chemotherapy
pts patients, CT chemotherapy, FAC 5-fluorouracil and doxorubicin and cyclophosphamide, DFS disease-free survival, EC epirubicin and cyclo-
phosphamide, OS overall survival, CMF cyclophosphamide and methotrexate and 5-fluorouracil, CTM cyclophosphamide and tiotepa and mitox-
antrone, EFS event free survival, AC doxorubicin and cyclophosphamide, T paclitaxel, TAC docetaxel and doxorubicin and cyclophosphamide, 
BCSS breast cancer-specific survival
References N Adjuvant chemotherapy type Cut-off point for BCL-2  
immuno-positivity/overexpression
BCL-2 prognostic significance
van Slooten et al. (1996) 423 202 pts: no adjuvant CT
221 pts: FAC
>75 % of cells with moderate or 
strong intensity
BCL-2 positivity: better DFS, lack 
of significance in multivariate 
analysis
Mottolese et al. (2000) 157 4 cycles of EC or
4 cycles of EC + lonidamine or
4 cycles of EC + G-CSF or
4 cycles of EC + lonid-
amine + G-CSF
>20 % of stained cells In the entire cohort: no significance 
in lobular carcinomas:
BCL-2 positivity: worse OS and 
DFS
Yang et al. (2003) 147 All pts: FEC BCL-2 positivity: better OS and 
DFS confirmed in multivariate 
analysis
Kröger et al. (2006) 157 78 pts: 3 cycles of CMF
79 pts: 4 cycles of 
EC → CTM → stem  
cell support
>0 % of stained cells BCL-2 positivity: better EFS, con-
firmed in multivariate analysis
Lee et al. (2007) 151 AC → T >0 % of stained cells BCL-2 positivity: better OS and 
DFS confirmed in multivariate 
analysis
Dumontet et al. (2010) 1,342 663 pts: FAC
679 pts: TAC
>70 % of stained cells BCL-2 positivity: better OS and 
DFS, lack of significance in  
multivariate analysis
Abdel-Fatah et al. (2010) 1,235 377 pts: no adjuvant treatment
382 pts: hormonal therapy
182 pts: CMF
32 pts: CMF + hormonal therapy
245 pts: anthracyclines
>10 % of stained cells The entire patient cohort and 
separately patients treated with 
anthracyclines:
BCL-2 positivity: better DFS and 
BCSS confirmed in multivariate 
analysis
Kim et al. (2010) 100 24 pts: no adjuvant treatment
30 pts: CMF
27 pts: doxorubicin containing CT
3 pts: others chemotherapy
16 pts: hormonal therapy only
>10 % of stained cells No significance
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procedure and cut-off points used to identified BCL-2 posi-
tivity and negativity (Table 1). Thus, there is still a need to 
evaluate the prognostic role of BCL-2 in BC patients.
The aim of the present study was to evaluate the prog-
nostic significance of BCL-2 expression in the group of 172 
women with breast cancer in clinical stage T1–T2, N1–N2, 
M0, treated with ATC in adjuvant settings. For this purpose, 
we assessed the correlation between this parameter and 
patient disease-free survival (DFS). Because in the present 
patient group we reanalysed follow-up data, we decided to 
assess once again the influence of all clinical (patients’ age 
tumour size, lymph node metastases, grade) and biological 
features (expression of steroid hormone receptors, cytoker-
atin 5/6 (CK5/6), HER2, TOPOIIα, Ki-67, P53 and MVD), 
which were previously studied (Biesaga et al. 2011, 2012) 
on DFS of breast cancer patients.
Materials and methods
Patients
This study was performed in the group of 172 patients 
with breast cancer who met the following criteria: (1) inva-
sive ductal breast cancer in clinical stage T1–T2, N1–N2, 
M0, (2) radical surgery (mastectomy or breast conserving 
therapy), (3) adjuvant anthracycline-based chemotherapy 
(according to two regimes: FAC—5-fluorouracil, doxoru-
bicin, cyclophosphamide or AC—doxorubicin, cyclophos-
phamide). All other details concerning this patient group 
were presented previously (Biesaga et al. 2011, 2012).
The study has been approved by the Ethics Committee 
at the Centre of Oncology, Krakow, Poland (date of issue 
14.02.2006).
Tumour samples
Formalin-fixed, paraffin-embedded tissue blocks were 
obtained from each patient, and serial 4-µm sections were 
processed for application of the immunohistochemistry 
(IHC).
Immunohistochemistry
In order to assess BCL-2 expression, IHC staining was 
performed on 5-μm-thick sections from routinely fixed 
paraffin-embedded blocks. To unmask antigen, the depar-
affinized (trough xylene series) and rehydrated sections 
(in decreasing concentrations of ethanol) were incubated 
for 50 min. in TRS (pH 6.1, DAKOCytomation, Glostrup, 
Denmark) preheated to 96 °C. Endogenous peroxidases 
were quenched by 30 min. incubation in 3 % hydrogen 
peroxide in 70 % methanol. Whole night incubation with 
diluted primary (1:40) antibody (Monoclonal Mouse Anti-
Human, BCL-2 Oncoprotein, Clone 124, DAKOCytoma-
tion, Glostrup, Denmark) at 4 °C in humidity chamber was 
carried out (Table 2). The antigen-primary antibody immu-
noreaction was detected by BrightVision Poly- HRP-Anti 
Ms/Rb/Rt IgG (ImmunoLogic, Duiven, the Netherlands). 
For this purpose, after three times washing in TBS-T, the 
slides were incubated at room temperature (RT) with post-
antibody blocking for 15 min and with poly-HRP-goat 
anti-mouse/rabbit IgG for 30 min. Peroxidase was visual-
ized using 0.01 % 3.3-diaminobenzidine tetrahydrochloride 
(DAB) and 0.015 % hydrogen peroxide. The slides were 
counterstained with Mayer’s haematoxylin. Tumour speci-
men with known strong BCL-2 expression added to each 
series of staining was treated as positive control. For nega-
tive control, TBS was substituted for the primary antibody.
Samples were analysed using Olympus microscope 
at 400× magnification. BCL-2 expression was scored 
according to classification presented by Treré et al. (2007), 
because based on it, they found significant relation between 
BCL-2 expression assessed by IHC and its mRNA level. 
According to this scale, three classes of BCL-2 expres-
sion were identified: 0—lack of immunostaining (no 
BCL-2 expression), 1—heterogeneous staining within 
tumour area, regardless of the intensity (BCL-2 expression) 
and 2—intense staining in all tumour cells (BCL-2 overex-
pression) (Fig. 1a–c).
All details regarding immunohistochemical analysis 
of steroid hormone receptors, CK5/6, HER2, TOPOIIα, 
Ki-67, P53 expression and MVD have been previously 
described (Biesaga et al. 2011, 2012) and in the present 
paper summarized in Table 2.
Breast cancer immunophenotypes were identified on 
the basis of ER, PgR, HER2 and Ki-67 labelling index 
(Ki-67LI) according to St. Gallen Expert Consensus (Gol-
dhirsch et al. 2013): luminal A-like (LA): ER and PgR 
positive, HER2 negative and Ki-67 “low” (in the present 
cohort ≤19.7 %), luminal B HER2− (LBHER2−): ER posi-
tive, HER2 negative and at least one of: Ki-67 “high” (in 
the present cohort >19.7 %) or PgR negative, luminal B 
HER2+ (LBHER2+): ER positive, HER2 overexpressed 
or amplified, any Ki-67, any PgR, HER2+: HER2 overex-
pressed or amplified, ER and PgR absent, triple negative 
(TN): ER and PgR absent, HER2 negative.
Statistical methods
All statistical analyses were carried out using Statistica v.10.0 
program (StatSoft, USA). Descriptive statistics were used to 
determine mean and median values of continuous variables 
and standard errors of means (SE). The significance of differ-
ences in continuous variables between groups was assessed 
on the basis of Mann–Witney U test. Independence of 
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categorical variables expressed in a cross-tab was analysed by 
Pearson’s chi-square test. Cumulative DFS probabilities were 
estimated using the Kaplan–Meier method, and the signifi-
cance of differences between survival rates was calculated by 
the log-rank test. Multivariate analysis was carried out using 
the Cox proportional hazards model, providing an estimate of 
the hazard ratio (HR) and a 95 % confidence interval (95 % 
CI). P value <0.05 was considered to be significant.
Table 2  Details of immunohistochemistry staining
IHC immunohistochemistry, ER oestrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, FISH fluores-
cence in situ hybridization; CK5/6 cytokeratin 5/6, TOPOIIα topoisomerase IIα
a
 Laica Biosystems Newcastle Ltd, Newcastle, UK
b
 DakoCytomation Denmark A/S, Glostrup, Denmark
c
 ImmunoLogic, Duiven, the Netherlands
Antigen Clone Source Dilution Detection 
system
Criteria for IHC positivity/overexpression
ER 6F11 Novocastraa 1:50 EnVisionb >10 % of tumour immunopositive cells
PgR 1A6 Novocastraa 1:50 EnVisionb >10 % of tumour immunopositive cells
HER2 – DAKOb 1:250 EnVisionb Strong complete uniform membrane staining in >30 % of tumour cells 
or complete membrane staining in >10 % of tumour cells confirmed 
by FISH
CK 5/6 D5/16 B4 DAKOb 1:50 EnVisionb >10 % of tumour immunopositive cells
TOPOIIα 3F6 Novocastraa 1:30 EnVisionb TOPOIIα labelling index (TOPOIIαLI—the percentage of TOPOIIα 
immunopositive tumour cells) >11.9 % (median value)
Ki-67 MIB-1 DAKOb 1:75 EnVisionb Ki-67 labelling index (Ki-67LI—the percentage of Ki-67 immunoposi-
tive tumour cells) >19.7 % (median value)
CD34 QBEnd 10 DAKOb 1:50 EnVisionb High microvessel density (MVD—mean number of microvessels per 
mm2 of tumour tissue) >210.0 vessels/mm2 (cut-off point found by 
minimal P value method)
P53 NCL-P53-1801 Novocastraa 1:40 EnVisionb P53 labelling (index (P53LI—the percentage of P53 immunopositive 
tumour cells) >10.0 %
BCL-2 124 DAKOb 1:40 BrightVisionc Intense staining in all tumour cells (class 2) or heterogeneous staining 
within tumour area, regardless of the intensity (class 1)
Fig. 1  Representative images 
of BCL-2 immunohistochemical 
staining in breast cancer tissue 
and correlation between BCL-2 
immunoexpression and other 
biological features studied. a 
Negative BCL-2 staining (class 
0—no BCL-2 expression). b 
Heterogeneous BCL-2 immu-
nostaining within tumour area 
(class 1—BCL-2 expression). 
c Intense BCL-2 staining in all 
tumour cells (class 2—BCL-2 
overexpression), ×200 mag-
nification. BCL-2 overexpres-
sion is correlated with d low 
proliferation rate assessed by 
Ki-67 labelling index (Ki-67LI), 
e low P53 level expressed as 
P53 labelling index (P53LI) 
(Kruskal–Wallis test)




A 172 patients with invasive ductal breast cancer were ana-
lysed (Table 3). Women aged from 32 to 78 years (with 
mean and median values 52.8 years ± 0.67 and 53 years, 
respectively). Among these, 54.7 % were in clinical stage 
T1N1, 23.3 % in stage T1N2, 18.0 % in T2N1 and 4.0 % 
in T2N2.
Most of the patients (89.0 %) were subjected to mas-
tectomy and 11 % underwent breast conserving surgery. 
All women received adjuvant anthracycline-based chemo-
therapy according to two regimes: six or four cycles of AC 
(59.9 % of patients) or six or four cycles of FAC (40.1 % of 
patients). The patients were assigned to these two regimes 
because in the Centre of Oncology, Krakow Branch, the 
period of time between 2001 and 2005, when patients were 
recruited for the study, was transition time in the use of 
FAC instead of AC for adjuvant anthracycline-based chem-
otherapy. Due to positive lymph nodes, all patients under-
went locoregional radiotherapy (45 Gy/2 Gy/day + boost 
or 50 Gy/2 Gy/day) as soon as possible after last chemo-
therapy course. All women with ER or PgR positivity 
(77.9 %) were treated with tamoxifen for 5 years. Women 
included in the study did not receive trastuzumab, because 
in Poland, trastuzumab has been used and reimbursed by 
the National Health Fund for the adjuvant treatment since 
2007.
All data regarding treatment outcome in this patient 
group were reanalysed in June 2012. In contrast to our 
earlier analyses (Biesaga et al. 2011, 2012) in which we 
obtained data for 167 patients, at present follow-up was 
available for 171 patients, one patient is still lost from 
follow-up. The mean and median length of follow-up 
were 61.8 months ± 1.9 (SE) and 69 months, respectively, 
(range 1–126 months). Tumour progression (locoregional 
recurrence, distant recurrence or second malignancy) was 
observed in 35 patients (20.5 %), after 1–70 months (mean 
and median values, respectively, 24.8 months ± 2.7 and 
24.0 months) after surgery.
BCL-2 expression, apoptosis level and correlations 
with clinicopathological features and other 
immunohistochemical markers
Due to accessibility of material in paraffin blocks in this 
series, the evaluation of BCL-2 expression was possible 
for 141 (82.0 %) out of 172 patients. According to BCL-2 
expression, 38/141 (27.0 %) were classified as 0 (no 
expression), 70/141 (49.6 %) as 1 (BCL-2 expression) and 
33/141 (23.4 %) as 2 (BCL-2 overexpression) (Table 3). 
BCL-2 overexpression was significantly related to lower 
tumour grades (P = 0.001), positive hormonal receptors 
status (P = 0.000) and CK5/6 negativity (P = 0.015). The 
significantly higher percentage of tumours overexpressing 
BCL-2 was also found in LA and LB than in HER2+ and 
TN cancer immunophenotypes, identified on the basis of 
ER, PgR, HER2 and Ki-67 expression according to St. Gal-
len International Expert Consensus on The Primary Ther-
apy of Early Breast Cancer 2013 (Goldhirsch et al. 2013).
BCL-2 expression status significantly correlates with 
Ki-67LI (P = 0.038) and P53 labelling index (P53LI) 
(P = 0.014), both analysed as categorical variables. Ki-
67LI was categorized using median value (19.7 %). In case 
of P53LI, we decided, similar to other authors (Malamou-
Mitsi et al. 2006; Mottolese et al. 2000), to accept the 
threshold for the P53 positivity at the level of 10 %. The 
percentage of BCL-2 overexpressed tumours was signifi-
cantly higher in lower proliferating cancers with P53 nega-
tivity. Similar relations between BCL-2 expression and Ki-
67LI or P53LI were also observed, if these two variables 
were analysed as continuous variables (Fig. 1d, e).
There was also a tendency suggesting associations 
between BCL-2 expression and patient age (P = 0.092) or 
HER2 status (P = 0.084); however, these relations did not 
reach statistical significance.
Univariate survival analysis
In the present patient cohort, the DFS was 78.8 %. Univari-
ate analysis showed the highest DFS (87.9 %) for women 
having tumours with BCL-2 overexpression (class 2), while 
the lowest (64.9 %) for those with BCL-2-negative cancers 
(class 0) (Table 4). Patients with BCL-2 expression in class 
1 were characterized by intermediate DFS (84.3 %). The 
differences in DFS according to BCL-2 expression were 
significant (P = 0.005).
The significant differences in DFS according to BCL-2 
expression classes were more apparent in the subgroup of 
younger patients (P = 0.0140), with T1 (P = 0.032), N1 
(P = 0.033) tumours, carcinomas characterized by nega-
tivity of CK5/6 (P = 0.043), HER2 (P = 0.019) and P53 
(P = 0.037), low MVD (P = 0.013) and only for patients 
with cancers having TN immunophenotype. In TN sub-
group, women with BCL-2 immunopositive (classes 1 + 2) 
tumours were characterized by 85.7 % of DFS, whereas 
those without BCL-2 expression by 38.5 % of DFS. This 
difference was statistically significant (P = 0.048).
Since we have updated follow-up data, in the present 
analysis, we also re-examined the relation between DFS 
and previously evaluated biological features of tumours 
studied (Biesaga et al. 2011, 2012). For this analysis, in 
case of three continuous variables: Ki-67LI, TOPOIIαLI 
and MVD, we checked the level of cut-off point by mini-
mum P value method from log-rank test. For Ki-67LI 
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and TOPOIIαLI, the cut-off point values remained at 
the same level as previously published (median values 
for both parameters) (Biesaga et al. 2011, 2012). For 
MVD, we changed the cut-off point from 214.8 to 210.0 
microvessels/mm2, as at this cut-off point, the highest 
level of significance was observed. DFS was significantly 
Table 3  Clinical and biological 
features of breast cancer 
patients stratifying according to 
BCL-2 expression
HER2 human epidermal growth 
factor receptor 2, TOPOIIαLI 
topoisomerase IIα labelling 
index, Ki-67LI Ki-67 labelling 
index, MVD microvessel 
density, P53LI P53 labelling 
index, LA luminal A, LB 












 Cut-off point from minimal P 
value method
e
 Immunophenotypes indicated 
on the basis of ER, PgR, HER2 
and Ki-67 expression according 
to St. Gallen International 
Expert Consensus on The 
Primary Therapy of Early 
Breast Cancer 2013 (Goldhirsch 
et al. 2013)
BCL-2 expression
All (%)1 0 1 2 P valuea
N (%)* N (%)* N (%)*
All (%) 141 (100) 38 (27.0) 70 (49.6) 33 (23.4)
Age
 <50 years 47 (33.3) 8 (17.0) 29 (61.7) 10 (21.3) 0.092
 ≥50 years 94 (66.7) 30 (31.9) 41 (43.6) 23 (24.5)
Tumour size
 T1 38 (27.0) 9 (23.7) 17 (44.7) 12 (31.6) 0.378
 T2 103 (73.0) 29 (28.1) 53 (51.5) 21 (20.4)
Nodal status
 N1 108 (76.6) 26 (24.1) 56 (51.8) 26 (24.1) 0.376
 N2 33 (23.4) 12 (36.4) 14 (42.4) 7 (21.2)
Grade
 G1 + G2 71 (50.4) 10 (14.1) 37 (52.1) 24 (33.8) 0.000
 G3 70 (49.6) 28 (40.0) 33 (47.1) 9 (12.9)
Oestrogen receptor status
 Positive 97 (68.8) 11 (11.0) 58 (58.0) 31 (31.0) 0.000
 Negative 44 (31.2) 28 (63.6) 14 (31.8) 2 (4.6)
Progesterone receptor status
 Positive 93 (66.0) 10 (10.7) 53 (57.0) 30 (32.3) 0.000
 Negative 48 (34.0) 28 (58.3) 17 (35.4) 3 (6.3)
Cytokeratin 5/6 expression
 Positive 30 (21.3) 13 (43.3) 15 (50.0) 2 (6.7) 0.015
 Negative 111 (78.7) 25 (22.5) 55 (49.6) 31 (27.9)
HER2 status
 Overexpressing 54 (38.3) 19 (35.2) 27 (50.0) 8 (14.8) 0.084
 Not overexpressing 87 (61.7) 19 (21.8) 43 (49.4) 25 (28.7)
TOPOIIαLIc
 ≤11.9 % 71 (50.4) 16 (22.5) 37 (52.1) 18 (25.4) 0.486
 >11.9 % 70 (49.6) 22 (31.4) 33 (47.1) 15 (21.4)
Ki-67LIc
 ≤19.7 % 74 (52.5) 15 (20.3) 36 (48.6) 23 (31.1) 0.038
 >19.7 % 67 (47.5) 23 (34.3) 34 (50.7) 10 (14.9)
MVDd
 ≤210.0 vessels/mm2 96 (68.1) 28 (29.1) 47 (49.0) 21 (21.9) 0.645
 >210.0 vessels/mm2 45 (31.9) 10 (22.2) 23 (51.1) 12 (26.7)
P53LI
 ≤10.0 % 100 (70.9) 20 (20.0) 55 (55.0) 25 (25.0) 0.014
 >10.0 % 41 (29.1) 18 (43.9) 15 (36.6) 8 (19.5)
Breast cancer immunophenotypese
 LA 42 (29.8) 5 (11.9) 19 (45.2) 18 (42.9) 0.000
 LB HER2− 22 (15.6) 0 (0.0) 16 (72.7) 6 (27.3)
 LB HER2+ 33 (23.4) 5 (15.2) 21 (63.6) 7 (21.2)
 HER2+ 21 (14.9) 14 (66.7) 6 (28.5) 1 (4.8)
 TN 23 (16.3) 14 (60.9) 8 (34.8) 1 (4.3)
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associated with histological grade (P = 0.001), ER 
(P = 0.017) or PgR (P = 0.045) status, CK5/6 expres-
sion (P = 0.021), TOPOIIαLI (P = 0.003) and MVD 
(P = 0.000) (Table 4). In case of P53 expression and can-
cer immunophenotypes, this relation was at significance 
border.
Table 4  Univariate Cox 
proportional hazard model for 
disease-free survival of 171 
breast cancer patients treated 
with adjuvant anthracycline-
based chemotherapy
HR hazard ratio, CI confidence 
interval, HER2 human 
epidermal growth factor 
receptor 2, Ki-67LI Ki-67 
labelling index, TOPOIIαLI 
topoisomerase IIα labelling 
index, MVD microvessel 
density, P53LI P53 labelling 
index, LA luminal A, LB 
luminal B, TN triple negative









 Immunophenotypes indicated 
on the basis of ER, PgR, HER2 
and Ki-67 expression according 
to St. Gallen International 
Expert Consensus on The 
Primary Therapy of Early 
Breast Cancer 2013 (Goldhirsch 
et al. 2013)
Response N (%) HR 95 % CI P value*
Age
 >50 years 90/115 (78.3) 1.080 0.534–2.189 0.830
 ≤50 years 45/56 (80.4) 1.000
Tumour size
 T1 45/52 (86.5) 1.000 0.846–4.374 0.109
 T2 90/119 (75.6) 1.924
Nodal status
 N1 107/132 (81.1) 1.000 0.783–3.214 0.206
 N2 28/39 (71.8) 1.587
Grade
 G1 + G2 81/92 (88.0) 1.000 1.508–6.198 0.001
 G3 54/79 (68.4) 3.057
Oestrogen receptor status
 Positive 102/123 (82.9) 1.000 0.262–1.021 0.017
 Negative 33/48 (68.8) 1.932
Progesterone receptor status
 Positive 98/119 (82.4) 1.000 0.296–1.150 0.045
 Negative 37/52 (71.2) 1.716
HER2 status
 Overexpressing 55/68 (80.9) 1.000 0.523–1.984 0.750
 Not overexpressing 80/103 (77.7) 1.019
Cytokeratin 5/6
 Positive 23/35 (65.7) 2.301 1.154–4.588 0.021
 Negative 112/136 (82.4) 1.000
Ki-67LIa
 ≤19.7 % 74/90 (82.2) 1.000 1.063–4.329 0.270
 >19.7 % 61/81 (75.3) 2.196
TOPOIIαLIa
 ≤11.9 % 73/83 (88.0) 1.000 1.376–5.886 0.003
 >11.9 % 62/88 (72.6) 2.846
MVDb
 >210.0 vessels/mm2 52/53 (98.1) 1.000 0.009–0.460 0.000
 ≤210.0 vessels/mm2 83/118 (71.3) 15.724
P53 LI
 >10.0 % 35/50 (70.0) 1.935 1.000–3.742 0.052
 ≤10 % 100/121 (82.6) 1.000
BCL-2 expression
 Class 0 24/37 (64.9) 2.873 0.156–0.776 0.005
 Class 1 59/70 (84.3) 1.302
 Class 2 29/33 (87.9) 1.000 0.246–2.401
Breast cancer immunophenotypesd
 LA 41/50 (80.8) 1.000 0.350–2.164 0.081
 LB HER2− 24/29 (79.6) 1.084
 LB HER2+ 37/44 (84.0) 1.094 0.386–2.410
 HER2+ 18/24 (74.5) 1.717 0.624–4.729
 TN 15/24 (62.5) 2.581 1.024–6.503
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Multivariate analysis
 The multivariate analysis included the variables for which 
in univariate analysis, significant differences or differ-
ences at significance border in DFS were seen, i.e. grade, 
hormone receptors status, CK5/6 expression, Ki-67LI, 
TOPOIIαLI, MVD, P53LI, BCL-2 expression and breast 
cancer immunophenotypes. BCL-2 expression was cat-
egorized into two classes: BCL-2 negativity (class 0) 
and positivity (classes 1 + 2). In case of breast cancer 
immunophenotypes, we stratified patients into two sub-
groups: those with LA and LB (HER2− and HER2+) carci-
nomas and those with HER2+ or TN tumours. Multivariate 
analysis revealed topoisomerase IIα expression, microves-
sel density and BCL-2 status as independent prognostic 
factors for adjuvant chemotherapy with anthracyclines 
(Table 5).
Based on these results, we decided to divide the ana-
lysed group into two subgroups of different prognosis: 
(1) women with tumours characterized by low TOPOαLI 
and high MVD and BCL-2 positivity (n = 18) and (2) the 
remaining patients (n = 153). All 18 patients from sub-
group 1 survived 80 months after treatment completion 
without any evidence of cancer disease, whereas DFS for 
women from subgroup 2 was 76.5 % (Fig. 2). The dif-
ference in DFS between these subgroups was significant 
(P = 0.022).
Discussion
In the present study, we have shown, to the best of our 
knowledge, for the first time, 100 % DFS for patients 
having tumours characterized by low topoisomerase IIα 
expression and high microvessel density and BCL-2 posi-
tivity (all assessed by immunohistochemistry). The results 
suggest that these three parameters may constitute an 
input into the new prognostication model specially dedi-
cated to adjuvant anthracycline-based chemotherapy of 
breast cancer patients. This suggestion is in agreement with 
other results showing that BCL-2 expression can improve 
prognostication of BC patients treated with different CT 
Table 5  Multivariate Cox regression analysis on disease-free sur-
vival of 171 breast cancer patients
TOPOIIαLI topoisomerase IIα labelling index, MVD microvessel 









 Immunophenotypes indicated on the basis of ER, PgR, HER2 and 
Ki-67 expression according to St. Gallen International Expert Con-
sensus on The Primary Therapy of Early Breast Cancer 2013 (Gol-
dhirsch et al. 2013)
HR 95 % CI P value
Grade
 1 + 2 1.000 0.611–4.176 0.329
 3 1.610
Oestrogen receptor status
 Positive 1.000 0.580–3.792 0.412
 Negative 1.484
Progesterone receptor status
 Positive 1.000 0.355–1.748 0.560
 Negative 1.269
Cytokeratin 5/6 expression
 Positive 1.801 0.782–4.144 0.169
 Negative 1.000
TOPOIIαLIa
 ≤11.9 % 1.000 1.202–6.303 0.017
 >11.9 % 2.752
MVDb
 >210.0 vessels/mm2 1.000 0.010–0.509 0.009
 ≤210.0 vessels/mm2 14.352
P53LI
 ≤10.0 % 1.000 0.536–2.679 0.662
 >10.0 % 1.198
BCL-2 expression
 Classes 1 + 2 1.000 0.153–0.699 0.004
 Class 0 3.056
Breast cancer immunophenotypesd
 LA + LB (HER2− and HER2+) 1.000 0.322–2.886 0.947
 HER2+ + TN 1.038
Fig. 2  Low topoisomerase IIα expression, high microvessel density 
and BCL-2 positivity indicate 100 % probability of 5-year disease-
free survival (DFS) of 18 patients with breast cancer. Women having 
tumours with other combination of these three biological features 
(n = 153) demonstrate significantly lower DFS (log-rank test)
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regimens. Abdel-Fatah et al. (2010), in the group of 245 
patients with invasive BC treated with adjuvant ATC-
based chemotherapy, found a good prognosis for patients 
with active or partially inactive P53 pathway (assessed by 
expression of BCL-2, p21, p27, hormone receptors, P53, 
Ki-67, EGFR, CK 5/6 and HER2 gene amplification status). 
In turn, Hwang et al. (2012) assessed prognostic influence 
of BCL-2 expression in the group of 7,230 primary BC 
patients in clinical stage 1, 2 or 3, of whom 4,532 received 
different systemic therapy. They have shown that the risk 
groups of cancer patients, identified by St. Gallen model 
or Nottingham Prognostic Index model or TNM staging, 
could be subdivided by addition of the BCL-2 assessment 
in all three models. Callagy et al. (2006) have also found 
that BCL-2 was the only marker from a panel of 13 pro-
teins (HER2, c-Myc, cyclin E, CK5/6, CK17, CK8/18, ER, 
Ki-67, MCM-2, p27, P53 and PgR) that improved prognos-
tication in the group of 930 breast cancer patients, some of 
whom were treated with adjuvant CT.
The positive prognostic significance of low TOPOIIα 
expression and high MVD is in concordance with results 
obtained by some authors (TOPOIIα: Fritz et al. 2005; 
Depowski et al. 2000; MVD: Gunel et al. 2002; Proto-
papa et al. 1993). The positive effect of low TOPOIIα may 
be explained by hypothesis suggesting that low enzyme 
expression is related to less aggressive tumour phenotype, 
characterized by low histological grade, hormone recep-
tors positivity, CK5/6 negativity and low proliferation 
rate, what was shown by us (Biesaga et al. 2011) and other 
authors (Fritz et al. 2005; Durbecq et al. 2004; Depowski 
et al. 2000). In turn, the positive influence of high MVD 
on ATC treatment outcome may be related to enhancement 
of production of reactive oxygen species under ATC or 
increased drug access to tumour cells in well-vascularized 
tumours. All these suggestions were carefully discussed in 
our earlier publications (Biesaga et al. 2011, 2012); there-
fore, in the present paper, we would like to focus on prog-
nostic potential of BCL-2 expression.
We have shown that BCL-2 expression is independent 
prognostic factor for adjuvant chemotherapy with ATC, 
what is in agreement with results of a few other reports in 
which analysis of subgroups of patients treated with ATC in 
adjuvant settings was provided (see Table 1). Some of these 
data were summarized in meta-analysis performed by Cal-
lagy et al. (2008), who included seventeen papers published 
since 2006, reporting data of almost 6,000 patients with 
BC, regardless of the treatment type. This meta-analysis 
supports that BCL-2 overexpression indicates good prog-
nosis. This effect was independent of lymph node status, 
tumour size or grade as well as a range of other biologi-
cal variables. However, another meta-analysis from 2013, 
in which 23 studies involving almost 2,500 BC patients, 
showed that negative BCL-2 expression was associated 
with pathological complete response in women treated with 
ATC-based neoadjuvant chemotherapy (Yang et al. 2013). 
We mentioned about the possible causes of these contrary 
results in Introduction section.
The reasons of positive prognostic potential of BCL-2 
overexpression are not fully understood. It is well known 
that this protein has oncogenic function related to inhibition 
of apoptosis and hence tumour progression and metastatic 
potential (Short and Johnstone 2012). However, in some 
types of tumour, BCL-2 seems to play both oncogenic and 
suppressive role. It is postulated that the dominance of one 
of these functions over another may depend on the cell 
type and physiology and that suppressive effect dominates 
in solid epithelial tumours including breast cancer (Zinkel 
et al. 2006). BCL-2 suppressive function may be a conse-
quence of its non-apoptotic functions, particularly its abil-
ity to control cell cycle machinery, what was supported by 
cell line studies in which relation between BCL-2 expres-
sion and G0 prolongation and delay of G1-S transition was 
shown (Zinkel et al. 2006; Pietenpol et al. 1994).
Positive prognostic significance of BCL-2 overexpres-
sion may be explained by its influence on BC cell chemo-
sensitivity. Del Bufalo et al. (2002) have shown that human 
BC cell lines overexpressing BCL-2 displayed an increased 
sensitivity to drugs known to induce multidrug resistance 
phenomenon (MDR) such as doxorubicin, vincristine, vin-
blastine and actinomycin, whereas they show increased 
resistance to drugs not related to the MDR (cisplatin and 
bischloroethylnitrosourea). The enhanced sensitivity to 
doxorubicin was associated with an increased drug accu-
mulation and its decreased efflux as well as with reduction 
of the adenosine triphosphate level and kinase C activity, 
both of which participate in the regulation of MDR. In ear-
lier studies, the above-referred authors have demonstrated 
that BCL-2 overexpression was related to inhibition of 
mitochondrial metabolism and reduction of oxygen uptake 
and 14CO2 production (Biroccio et al. 1999).
The positive prognostic power of BCL-2 overexpression 
may be also related to its correlation with other favourable 
prognostic markers such as lower tumour grade, oestrogen 
and progesterone positivity, cytokeratin negativity, lack of 
HER2 overexpression, which was shown in our study and 
is in agreement with other authors (van Slooten et al. 1996; 
Mottolese et al. 2000; Yang et al. 2003; Lee et al. 2007; 
Kim et al. 2010). We have also found the higher percent-
age of BCL-2-positive tumours among luminal A and B 
cancer immunophenotypes as compared with HER2+ and 
TN immunophenotypes. Therefore, BCL-2 expression may 
also reflect lower degree of tumour differentiation.
In the presented analysis, based on BCL-2 expression, 
we could stratify patients with triple negative tumours into 
two subgroups with different prognosis. TN breast can-
cer patients with BCL-2 overexpression had significantly 
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higher DFS than those with BCL-2 negativity. These 
results should be, however, interpreted with care, because 
of the small number of patients in each subgroup (7 and 
13, respectively). Nonetheless, presented results are partly 
in agreement with those obtained by other authors. Abdel-
Fatah et al. (2013) in the large cohort of 635 patients with 
early advanced TN breast cancers have found that BCL-2 
negativity was associated with approximately twice the risk 
of death and recurrence in patients who did not receive CT 
or were treated with CMF. In turn, they have shown longer 
survivals in BCL-2-negative TN BC patients exposed to 
anthracyclines than in those who did not receive chemo-
therapy or were treated with CMF. Relatively high DFS in 
BCL-2-positive TN tumours obtained by us could also con-
firm results of earlier reports, showing that a subset of TN 
breast cancer patients responded to standard chemotherapy 
and had survival rate similar to women with other breast 
cancer immunophenotypes (Liedtke et al. 2008). However, 
Tawfik et al. (2012), contrary to us, have demonstrated 
association between BCL-2 positivity and poorer survival 
only among non-TN breast cancer patients, whereas in the 
group of TN breast cancer patients, BCL-2 status had no 
influence on treatment outcome. These discrepancies may 
be explained by heterogeneity of TN subtype, which rep-
resents distinct molecular subgroups that differentially 
respond to chemotherapy. Lehmann et al. (2011), analysing 
gene expression profiles, have identified six distinct molec-
ular subtypes of TNBC including two basal like, an immu-
nomodulatory, a mesenchymal, a mesenchymal stem-like 
and a luminal androgen receptor subtype. In the next report 
of this team, in the group of 130 patients with TN BC who 
received neoadjuvant chemotherapy containing sequential 
taxane and ATC chemotherapy, significant relation between 
TN BC subtypes and pathological complete response status 
was found (Masuda et al. 2013). Thus, in the light of our 
and some other author’s results, we postulate that BCL-2 
expression may be one of the surrogate markers allowing 
distinguishing TN BC subtypes with different sensitivity 
to ATC; however, this supposition requires confirmation in 
further studies.
In conclusion, in the present study, we have shown, to 
the best of our knowledge for the first time, that by com-
bination of three parameters: BCL-2 positivity, low topoi-
somerase IIα expression and high microvessel density, it 
is possible to identify subgroups of BC patients with very 
good prognosis after adjuvant anthracycline-based chemo-
therapy. All these three parameters were assessed by immu-
nohistochemistry, which is an inexpensive and routine 
method, widely used in pathology and radiobiology depart-
ments. Therefore, assessment of these proteins is easy for 
implementation in daily clinical practise. However, the pre-
sented results should be confirmed in larger, prospective 
clinical trials.
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